The realization that they were not alone set the tone for MDA Engage: Chicago, a free symposium held Sept. 26 in suburban ...

The Phase 2b/3 trial (NCT04057898) is testing MN-166’s safety and efficacy at slowing disease progression in 234 adults with ALS. After an initial one-year part in which patient ...

Voice Back allows people with ALS and other conditions that affect speech communicate in a voice that sounds like their own.

These types of friends are irreplaceable and more embedded in our lives and hearts than others. Deep friendship requires each friend to call upon the other for help and support, even in the most ...

For people with muscular dystrophy, who may experience problems with muscle strength, endurance, balance, joint stiffness, ...

Low muscle mass and sarcopenia were linked to poorer survival in people with ALS. ASMI showed the strongest ability among the ...

Noninvasive ventilation, cough-assist devices, and breathing exercises are among ways ALS patients can ease breathing issues. Early signs of weakening breathing function can be subtle. Patients should ...

But what about all our plans?” I asked my husband right after receiving my ALS diagnosis in 2024. “We’ve got places to go, ...

These groundbreaking results offer hope for the FUS-ALS community and represent an exciting milestone in our efforts to transform the treatment of this rare, rapidly progressive and fatal form of ...

I try to remind myself that there are glorious days of fall to enjoy yet. Crisp nights will bring out the autumn colors, and we’ll have warm days to view a patchwork of colored leaves. The grapes just ...

Coya has received IND (Investigational New Drug) approval to test Coya 302 in FTD. This trial will apply the same Treg-restoration science to a different neurodegenerative disease. Recruitment will ...

Acelot has dosed the first healthy volunteer in a Phase 1a clinical trial testing ACE-2223, its investigational oral treatment candidate designed to target aggregated TDP-43 in people with amyotrophic ...